Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 552
- Registration Number
- NCT00049595
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇧🇪Clinique Universitaire De Mont-Godinne, Yvoir, Belgium
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 50
- Registration Number
- NCT00002715
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 27
- Registration Number
- NCT00047229
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00028964
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-01-21
- Target Recruit Count
- 1500
- Registration Number
- NCT00003728
- Locations
- 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷CHR de Besancon - Hopital Saint-Jacques, Besancon, France
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 76
- Registration Number
- NCT00026208
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 265
- Registration Number
- NCT00024167
- Locations
- 🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸University of Mississippi Cancer Clinic, Jackson, Mississippi, United States
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 106
- Registration Number
- NCT00049036
- Locations
- 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT00006125
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸Lenoir Memorial Hospital Cancer Center, Kinston, North Carolina, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3222
- Registration Number
- NCT00021255
- Locations
- 🇻🇪
Sanofi-Aventis Administrative Office, Caracas, Venezuela
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.